RAPP Stock Analysis: Buy, Sell, or Hold?
RAPP - Rapport Therapeutics, Inc. Common Stock
$27.69
-0.15 (-0.54%)
▼
5d:
-0.79%
30d:
-4.62%
90d:
-8.31%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Distribution
RAPP is up 8.7% this week, but smart money is buying puts. Top strike: $30 2026-05-15 with 30 OI. Put ratio: 63% View Scanner →
Strength: 5.7/10
Get Alerted When RAPP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RAPP shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: RAPP shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: RAPP is currently trading at $27.69, which is considered slightly low relative to its 30-day fair value range of $27.68 to $29.90.
Technical Outlook: Technically, RAPP is in a uptrend. Immediate support is located at $26.01, while resistance sits at $30.72.
Market Sentiment: RAPP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.22 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RAPP is in a uptrend. Immediate support is located at $26.01, while resistance sits at $30.72.
Market Sentiment: RAPP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.22 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$27.68 -
$29.90
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.6% below Wall St target ($52.22)
Fair Price Analysis
30-Day Fair Range
$27.68 -
$29.90
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$3.03
(10.9%)
Support & Resistance Levels
Support Level
$26.01
Resistance Level
$30.72
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.12
Wall Street Target
$52.22
(+87.6%)
Share & Embed Analysis
Last updated: March 30, 2026 4:51 PM ET
Data refreshes hourly during market hours. Next update: 5:51 PM
Data refreshes hourly during market hours. Next update: 5:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RAPP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Cheryl Gault
SELL
2014 shares
2026-03-05
Abraham Ceesay
SELL
5833 shares
2026-02-18
Abraham Ceesay
SELL
5083 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 54 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |